B. Riley Has Negative Estimate for Verastem Q2 Earnings

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Stock analysts at B. Riley lowered their Q2 2025 earnings estimates for Verastem in a research report issued on Monday, April 28th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings of ($0.56) per share for the quarter, down from their prior forecast of ($0.53). B. Riley has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. B. Riley also issued estimates for Verastem's Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.98) EPS, FY2026 earnings at ($1.21) EPS and FY2028 earnings at $0.99 EPS.

Verastem (NASDAQ:VSTM - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.57).

VSTM has been the topic of a number of other research reports. Mizuho dropped their price objective on Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. HC Wainwright raised their price objective on shares of Verastem from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Monday, March 24th. Jefferies Financial Group assumed coverage on shares of Verastem in a research note on Thursday, April 10th. They issued a "buy" rating and a $15.00 price objective on the stock. Guggenheim raised their target price on shares of Verastem from $13.00 to $14.00 and gave the stock a "buy" rating in a report on Monday, March 24th. Finally, Royal Bank of Canada dropped their price target on Verastem from $16.00 to $14.00 and set an "outperform" rating on the stock in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $13.89.

Verastem Price Performance

VSTM traded down $0.38 on Thursday, reaching $6.63. The company had a trading volume of 561,725 shares, compared to its average volume of 1,035,435. Verastem has a one year low of $2.10 and a one year high of $13.52. The company has a market capitalization of $341.38 million, a P/E ratio of -2.07 and a beta of 0.57. The company has a fifty day moving average of $6.26 and a 200-day moving average of $5.38. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77.

Institutional Investors Weigh In On Verastem

A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Verastem by 51.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 1,698 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Verastem by 55.4% in the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 6,016 shares during the last quarter. ProShare Advisors LLC purchased a new position in Verastem in the fourth quarter valued at about $56,000. Voya Investment Management LLC acquired a new position in Verastem in the 4th quarter worth about $59,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Verastem during the 4th quarter valued at about $61,000. 88.37% of the stock is currently owned by institutional investors and hedge funds.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.